What is Letrozole toxicity?
Letrozole toxicity (Orphanet code 529831) refers to adverse effects resulting from exposure to letrozole, a non-steroidal aromatase inhibitor primarily used in the treatment of hormone receptor-positive breast cancer in postmenopausal women and sometimes used off-label for ovulation induction. Letrozole works by inhibiting the enzyme aromatase, which converts androgens to estrogens, thereby dramatically reducing circulating estrogen levels. Toxicity from letrozole can affect multiple body systems, most notably the musculoskeletal, cardiovascular, and skeletal systems. Key clinical features of letrozole toxicity include musculoskeletal complaints such as arthralgia, myalgia, and bone pain, which are among the most commonly reported adverse effects. Significant reduction in estrogen levels can lead to accelerated bone mineral density loss and increased fracture risk (osteoporosis). Cardiovascular effects may include hypercholesterolemia and, in some cases, increased risk of cardiovascular events. Other reported symptoms include hot flashes, fatigue, headache, dizziness, nausea, and peripheral edema. Hepatotoxicity, though rare, has been documented. Management of letrozole toxicity is primarily supportive and involves dose adjustment or discontinuation of the drug when toxicity is significant. Bisphosphonates or other bone-protective agents may be used to mitigate skeletal effects. Monitoring of bone density, lipid profiles, and liver function is recommended during treatment. In cases of acute overdose, general supportive measures and symptomatic treatment are employed, as there is no specific antidote for letrozole toxicity.
- Age of Onset
- Adult
- Begins in adulthood (age 18 or older)
Treatments
Source: openFDA + DailyMed · NDA / BLA labels with structured indications · refreshed weekly
No FDA-approved treatments are currently listed for Letrozole toxicity.
View clinical trials →Clinical Trials
View all trials with filters →Source: ClinicalTrials.gov · synced daily · phases, status, and PI names normalized at ingest
No actively recruiting trials found for Letrozole toxicity at this time.
New trials open frequently. Follow this disease to get notified.
Source: NPI Registry + PubMed · trial PI roles cross-referenced with ClinicalTrials.gov · ranked by match score (publications + PI activity + community signal)
Treatment Centers
8 centersSource: NORD Rare Disease Centers + NIH Undiagnosed Diseases Network (UDN) · centers verified active within last 12 months
Children's Hospital Colorado Rare Disease Program ↗
Children's Hospital Colorado
📍 Aurora, CO
👤 Boston Children's Hospital Rare Disease Program
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDBoston Children's Hospital Rare Disease Program ↗
Boston Children's Hospital
📍 Boston, MA
👤 Boston Children's Hospital Rare Disease Program
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
🏨 Children'sAnn & Robert H. Lurie Children's Hospital Genetics ↗
Lurie Children's Hospital
📍 Chicago, IL
👤 Boston Children's Hospital Rare Disease Program
🏥 NORDCincinnati Children's Hospital Medical Center ↗
Cincinnati Children's
📍 Cincinnati, OH
👤 Boston Children's Hospital Rare Disease Program
🏨 Children'sNationwide Children's Hospital Rare Disease Center ↗
Nationwide Children's Hospital
📍 Columbus, OH
👤 Boston Children's Hospital Rare Disease Program
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
Travel Grants
No travel grants are currently matched to Letrozole toxicity.
Community
No community posts yet. Be the first to share your experience with Letrozole toxicity.
Start the conversation →Latest news about Letrozole toxicity
Source: PubMed + NIH RePORTER + openFDA + clinical-journal RSS · last 30 days · disease-tagged at ingest by AI extraction with human QC
No recent news articles for Letrozole toxicity.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Letrozole toxicity
What is Letrozole toxicity?
Letrozole toxicity (Orphanet code 529831) refers to adverse effects resulting from exposure to letrozole, a non-steroidal aromatase inhibitor primarily used in the treatment of hormone receptor-positive breast cancer in postmenopausal women and sometimes used off-label for ovulation induction. Letrozole works by inhibiting the enzyme aromatase, which converts androgens to estrogens, thereby dramatically reducing circulating estrogen levels. Toxicity from letrozole can affect multiple body systems, most notably the musculoskeletal, cardiovascular, and skeletal systems. Key clinical features of
At what age does Letrozole toxicity typically begin?
Typical onset of Letrozole toxicity is adult. Age of onset can vary across affected individuals.
Which specialists treat Letrozole toxicity?
1 specialists and care centers treating Letrozole toxicity are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.
Frequently asked questions about Letrozole toxicity
Auto-generated from canonical disease facts (Orphanet, OMIM, ClinicalTrials.gov, openFDA, NPPES). Not a substitute for clinical guidance.
What is Letrozole toxicity?
Letrozole toxicity is a rare disease catalogued in international rare-disease ontologies (Orphanet ORPHA:529831). Inheritance pattern depends on the specific subtype. Age of onset is generally adult. For verified primary sources, see the UniteRare Letrozole toxicity page.
Are there FDA-approved treatments for Letrozole toxicity?
Approved treatments for Letrozole toxicity are tracked from openFDA and DailyMed primary sources. Many rare diseases have no specific FDA-approved therapy; for those, supportive care and management of complications form the basis of clinical care. Orphan-drug-designation status is noted where applicable.
Are there clinical trials for Letrozole toxicity?
Active clinical trials for Letrozole toxicity are tracked daily from ClinicalTrials.gov. Trial availability changes frequently; check the UniteRare trial listings for the current count and recruitment status. Sponsors of rare-disease research often welcome inquiries even when a trial is not actively recruiting at a given moment.
How do I find a specialist for Letrozole toxicity?
UniteRare lists 1 verified clinician with documented expertise in Letrozole toxicity, sourced from ClinicalTrials.gov principal-investigator records, PubMed publication histories, and the NPPES NPI registry. Filter by state or browse our state-specific specialist pages for nearby options.
See full Letrozole toxicity page for complete clinical details, sources, and verified-specialist listings.
Cite this page
Select a citation format above to view and copy.